Something significant is about to happen for millions of Medicare beneficiaries, and if you’ve been watching the news about weight-loss medications and wondering whether any of this applies to you, the answer might finally be yes. Starting July 1, 2026, Medicare is launching the GLP-1 Bridge Program, the first time in the program’s history that it will cover prescription weight-loss drugs. That’s not a small thing. Federal law has blocked Medicare Part D from paying for weight-loss medications since Part D launched back in 2006, a full twenty years. What changes in just a matter of days is the result of CMS (the Centers for Medicare and Medicaid Services) using its authority to run a demonstration project as a creative workaround while Congress hasn’t yet acted to change the underlying law permanently.

What the GLP-1 Bridge Actually Is, and Why It’s Different from Your Regular Part D Coverage

You might be wondering why this is called a “Bridge” and not just regular drug coverage. Here’s what I tell people: think of it as a temporary lane that CMS built alongside the existing highway, because the rules of the highway itself haven’t changed yet.

The Bridge runs from July 1, 2026 through December 31, 2027. It operates completely outside your standard Part D benefit. CMS is running a centralized system to handle prior authorization and claims, which means this doesn’t work the way most of your other prescriptions do. You won’t just hand your pharmacist your Part D card and walk out with Wegovy. There’s a separate approval process through CMS specifically for this program.

The practical upshot: if you’re approved, you pay a flat $50 per month. That’s your total out-of-pocket cost, full stop. CMS confirmed in its May 6, 2026 press release that manufacturers Novo Nordisk and Eli Lilly are providing these medications to the government at a net price of $245 per 30-day supply, with the program covering the gap between that cost and your $50 copay.

One more important note on timing: CMS announced in May 2026 that the follow-on program called the BALANCE Model, which would have folded GLP-1 coverage into regular Part D, is delayed indefinitely. That’s why the Bridge has been extended as the only pathway through 2027. Nobody should count on anything beyond December 31, 2027 without an act of Congress.

Which Drugs Are Covered (and Which Ones People Assume Are Covered But Aren’t)

Recommended OMRON Bronze Upper Arm Blood Pressure Monitor

Stores unlimited readings via app, clinically validated for accurate home blood pressure monitoring.

Check Price →
MedicationForm(s)Coverage StatusNotes
WegovyInjectable and tabletCoveredBoth formulations included
ZepboundKwikPen onlyCoveredOther formulations not covered
FoundayoInjectableCoveredAdded April 6, 2026
OzempicInjectableNot coveredApproved for diabetes, not weight loss
MounjaroInjectableNot coveredApproved for diabetes, not weight loss

Helpful resource: MedCenter 31-Day Monthly Pill Organizer is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)

Three medications are covered under the Bridge. Wegovy, available in both its injectable form and its newer tablet form. Zepbound, but only in the KwikPen formulation. And Foundayo, which received FDA approval and was added to the program on April 6, 2026.

Here’s where I see a lot of confusion, and it’s completely understandable given how much these medications get grouped together in news coverage. Ozempic and Mounjaro are explicitly excluded. Both of those drugs are approved for type 2 diabetes management, not specifically for weight loss, which is why they sit in a different regulatory and coverage category. If your doctor has been prescribing you Ozempic or Mounjaro for weight management, that does not automatically translate into Bridge eligibility or coverage. The approved drug list matters here.

If you’re unsure whether a medication your doctor recommends falls under the Bridge, the CMS Medicare GLP-1 Bridge page is the authoritative source to check, and your prescribing physician should be working with the updated guidance the AMA circulated as recently as June 26, 2026.

Do You Qualify? Understanding the BMI Thresholds

This is the question I hear most often, and the eligibility rules are actually more nuanced than a single cutoff number. You’ll need to be enrolled in Medicare Part D first. Beyond that, the BMI (body mass index) thresholds work in tiers depending on what other health conditions you have.

If your BMI is 35 or higher, you may qualify based on that alone. If your BMI is 30 or higher, you may qualify if you also have heart failure, uncontrolled hypertension, or chronic kidney disease. And if your BMI is 27 or higher, you may qualify if you have a history of pre-diabetes, a prior heart attack, a prior stroke, or peripheral artery disease.

A few things worth thinking through: BMI is a starting point, not the whole picture, and your doctor will need to document your qualifying condition as part of the prior authorization process. The Medicare Rights Center’s June 4, 2026 coverage of the program notes that the centralized CMS authorization system is new territory for many providers, so it may be worth asking your doctor specifically whether they’ve already reviewed the Bridge’s authorization process before your July appointment.

Also, nobody should self-diagnose their eligibility from an article. These thresholds come with specific clinical definitions, and a qualified healthcare provider, ideally one who knows your full medical history, is the right person to assess whether you meet them.

What to Do Right Now If You Think You Might Be Eligible

You don’t need to wait for July 1 to start the conversation. In fact, getting ahead of this is smart, because the program is new for everyone, including pharmacies and provider offices.

Talk to your doctor before July if you can. Ask them whether the Bridge is something they’ve reviewed and whether your health profile could qualify. Ask specifically whether they’re familiar with the CMS centralized prior authorization process, because this isn’t the standard workflow most offices use.

The NCOA (National Council on Aging) has published a detailed breakdown of the program’s eligibility and costs that’s worth reading alongside what your doctor tells you. And Medicare.gov remains your best starting point for confirming any details about your specific Part D plan and how it intersects with a demonstration program like this one.

One honest caution: because the Bridge runs outside normal Part D channels, there will likely be a learning curve in the first few weeks. Don’t be surprised if your pharmacy needs some time to understand how to process these claims. Patience and persistence will matter.

This is genuinely new ground for Medicare, and for many people living with obesity-related conditions, it’s the first real opening they’ve had. Whether it leads to a permanent change in federal law is still an open question, but for right now, through the end of 2027, access exists that didn’t exist before. That’s worth paying attention to.

Sources

This article is for informational purposes only. Medicare rules change annually. Always verify current plan details at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). This site does not sell insurance or recommend specific plans.

Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.

  • Medicare For Dummies (~$22), The definitive consumer guide to Medicare, enrollment windows, Part A/B/C/D, and supplement plans.
  • Get What’s Yours for Medicare (~$17), Maximize your Medicare benefits and minimize out-of-pocket costs. Covers Part D drug coverage gaps and Medigap in depth.